Stereospecific inhibition of AMPK by (R)-crizotinib induced changes to the morphology and properties of cancer and cancer stem cell-like cells

Crizotinib is used in the clinic for treating patients with ALK- or ROS1-positive non-small-cell lung carcinoma. The objective of the present study was to determine if crizotinib enantiomers could induce changes to the properties of cancer and cancer stem cell (CSC)-like cells at a high concentratio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of pharmacology 2021-11, Vol.911, p.174525, Article 174525
Hauptverfasser:	Kim, Tae Hyun, Park, Jong Hyeok, Park, Jooyeon, Son, Dong Min, Baek, Ji-Young, Jang, Hee Jun, Jung, Won Ki, Byun, Youngjoo, Kim, Sang Kyum, Park, Song-Kyu
Format:	Artikel
Sprache:	eng
Schlagworte:	AMP-Activated Protein Kinases - metabolism AMPK Animals Antineoplastic Agents - pharmacology Cancer Cell Line, Tumor Cell Proliferation - drug effects Crizotinib Crizotinib - pharmacology Enantiomer Gene Expression Regulation, Neoplastic - drug effects Humans Mice Morphology Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - pathology Protein Kinase Inhibitors - pharmacology Pyrazoles - pharmacology Pyridines - pharmacology Stereoisomerism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!